The US AS biosimilar market — dramatically transformed by the wave of adalimumab biosimilar launches following the January 2023 Humira patent cliff — is creating competitive market dynamics that are progressively reducing anti-TNF biologic costs for US payers and creating formulary complexity for American AS patients and rheumatologists, with the US Sacroiliitis Treatment Market reflecting the biosimilar revolution in US AS biologic economics.

Adalimumab biosimilar market — with over a dozen FDA-approved adalimumab biosimilars including Amjevita, Hadlima, Hyrimoz, Cyltezo, Hulio, and Simlandi competing with branded Humira — has created the most competitive biosimilar market globally, with US adalimumab list prices declining and net prices after manufacturer rebates declining even further. Pharmacy benefit managers leveraging biosimilar competition against Humira through preferential formulary placement have driven unprecedented adalimumab price competition.

Interchangeable biosimilar designation in the US — FDA's determination that designated biosimilars can be automatically substituted by pharmacists without prescriber notification in states permitting automatic substitution — creates a biologic-specific pharmacy substitution mechanism that does not exist in most other global markets. Cyltezo receiving the first adalimumab interchangeable designation and other biosimilars pursuing interchangeability represents the evolving US biosimilar market infrastructure.

Formulary management of adalimumab biosimilars — with different PBMs preferring different biosimilar manufacturers based on rebate negotiation, creating patient experience challenges when biosimilars preferred by different pharmacy channels conflict — represents the commercial complexity that biosimilar market maturation in the US creates for AS patients whose insurance changes may require biologic product switching.

Do you think the US adalimumab biosimilar market's price competition will eventually reduce adalimumab therapy cost to levels comparable to European biosimilar pricing that is already dramatically lower than US originator pricing?

FAQ

How many adalimumab biosimilars are available in the US for AS? Over a dozen FDA-approved adalimumab biosimilars are available in the US following the January 2023 Humira patent expiration; interchangeable biosimilars including Cyltezo may be automatically substituted by US pharmacists in states permitting interchangeable biosimilar substitution without prescriber notification.

What is an interchangeable biosimilar designation from FDA? FDA interchangeable biosimilar designation certifies that the biosimilar can be substituted for the reference product without prescriber involvement, enabling pharmacist-level automatic substitution; Cyltezo received the first adalimumab interchangeable designation, followed by other adalimumab biosimilars achieving this status.

#USSacroiliitis #USbiosimilarAS #AdalimumabBiosimilarUS #HumirabiosimilarUS #InterchangeableBiosimilar #USbiologicsPricing